Archives
-
FAISL–FAK Proteolysis in Triple-Negative Breast Cancer
2026-09-20
The reference study identifies FAISL as a long noncoding RNA that stabilizes focal adhesion kinase by blocking Calpain 2-mediated proteolysis, thereby promoting triple-negative breast cancer progression and metastasis. Its combination of transcriptomic discovery, mechanistic protein-interaction analysis, functional assays, and nanoparticle-enabled RNA interference provides a framework for studying post-translational regulation of FAK in TNBC.
-
Imatinib in Gastric Cancer Assembloid Research
2026-09-19
Imatinib (STI571) can serve as a mechanistic perturbation tool in patient-derived gastric cancer assembloids. This article explains how matched tumor–stroma models refine kinase-inhibition assays, reveal context-dependent drug responses, and define the limits of translating biochemical potency into tumor biology.
-
Vasopressin Analogues: Evidence and Research Implications
2026-09-18
The 2022 review by Glavaš and colleagues explains how structural changes to vasopressin reshape receptor activity, proteolytic stability, duration, and therapeutic utility. Its comparison of lypressin, desmopressin, terlipressin, and related peptides provides a practical framework for endocrine, vascular, and early antiviral research while emphasizing the limits of cross-domain evidence.
-
Palmitic acid: Protocol and QC Guide
2026-09-18
This guide explains how to select, reconstitute, document, and quality-check Palmitic acid (SKU N2456) for defined lipid and metabolic workflows. It is suitable for solvent-based in vitro studies but should not be used in aqueous-only protocols or for long-term storage of prepared solutions.
-
AT13387 Hsp90 Inhibitor Workflow Guide
2026-09-17
AT13387 supports quantitative cancer biology workflows that connect Hsp90 chaperone inhibition with client-protein loss, cell cycle arrest, and apoptosis induction. Its distinct scaffold, high reported affinity, and practical solubility profile also make it useful for separating cytotoxicity from membrane-rupture and secretion phenotypes.
-
DeferoxamineB in Ferroptosis Assay Design
2026-09-17
DeferoxamineB is most useful as a mechanistic iron-chelation tool for separating iron-dependent cytotoxicity from copper-driven and metabolism-driven effects. This workflow-focused guide covers stock preparation, factorial cell assays, interpretation, and troubleshooting for oncology and oxidative-stress research.
-
Ibotenic Acid Workflows for Neural Models
2026-09-16
Build more interpretable neural injury and excitotoxicity studies with a workflow that separates acute signaling from later structural outcomes. This guide combines practical preparation, time-resolved readouts, and troubleshooting for using Ibotenic acid as an NMDA receptor agonist in cell and animal research.
-
CDELNs Restore Sertoli Cell Cycle After Testicular Injury
2026-09-16
This study identifies Cistanche deserticola exosome-like nanovesicles (CDELNs) as a plant-derived intervention for cyclophosphamide-induced testicular injury. Its central mechanistic finding is that CDELN-delivered miR159b-3p targets P21 in Sertoli cells, helping restore CDK1 activity and relieve cell cycle arrest.
-
Metabolic Sensitization of Ferroptosis and Cuproptosis
2026-09-15
The 2024 Chemical Engineering Journal study develops a Cu-tannic acid/liposome nanosystem that combines copper delivery with STF-31-mediated inhibition of glycolysis and NAD+ metabolism. By reducing metabolic and redox buffering capacity, the platform synchronously sensitizes tumor cells to cuproptosis and ferroptosis while also promoting antitumor immune activity.
-
DeferoxamineB in Ferroptosis Research
2026-09-15
DeferoxamineB gives cancer researchers a practical iron-chelation tool for separating iron-dependent oxidative death from broader metabolic effects. This guide connects product handling, assay design, and the ferroptosis/cuproptosis strategy reported in Chemical Engineering Journal to create more interpretable cell-based workflows.
-
CENPI Drives Breast Cancer via Wnt/β-Catenin
2026-09-14
Wu et al. identify centromere protein I (CENPI) as an oncogenic driver of breast cancer and connect its activity to Wnt/β-catenin signaling. By combining clinical data, cellular and xenograft models, transcriptomics, and pathway reporter validation, the study provides a mechanistic framework for evaluating CENPI as a biomarker and potential therapeutic target.
-
DeferoxamineB as an Iron-Control Tool in Cancer Assays
2026-09-14
DeferoxamineB provides a mechanistic way to test whether iron availability contributes to oxidative cell death. This article explains how to use Deferoxamine alongside metabolic ferroptosis and cuproptosis models without mistaking iron chelation for proof of a single death pathway.
-
Chloroquine Workflows for Autophagy Assays
2026-09-13
Build reproducible Chloroquine experiments for lysosomal, autophagy, cancer, inflammatory, and antiviral research. This guide separates literature-backed concentration ranges from practical starting conditions and shows how to avoid mistaking in vitro antiviral activity for clinical efficacy.
-
Ibotenic Acid: From Receptor Agonism to Translation
2026-09-12
Ibotenic acid is more than an NMDA receptor agonist: it is a controlled perturbation tool for connecting glutamatergic signaling, neuronal activity, tissue injury, and translational model design. This article interprets recent murine toxicity evidence and offers practical guidance for building reproducible neuroscience workflows with appropriate safety and evidentiary boundaries.
-
Dual SMAD/Wnt Inhibition for iPSC-RGCs
2026-09-11
The reference study presents a chemically defined, non-genetic method for directing induced pluripotent stem cells toward retinal ganglion cells through coordinated SMAD and canonical Wnt inhibition. Its reproducibility, high RGC yield, and subsequent Thy-1 enrichment provide a useful framework for glaucoma modeling and comparative studies of retinal neurodegeneration.